<DOC>
	<DOCNO>NCT00936026</DOCNO>
	<brief_summary>Primary : To assess effect CYP2B6 inhibition repeat dose Clopidogrel ( 75 mg/day ) co-administration single-dose pharmacokinetics Neramexane Secondary : To assess safety tolerability Neramexane single dose treatment alone co-administration Neramexane single-dose Clopidogrel repeat dose treatment</brief_summary>
	<brief_title>Open , Single Center , Three Periods , Fixed Sequence Design Study Effects Clopidogrel Co-administration Pharmacokinetics Neramexane</brief_title>
	<detailed_description />
	<criteria>1 . Healthy adult subject white origin , able read , write fully understand German language 2 . Aged 18 45 year 3 . BMI 1828 kg/m2 body weight 5090 kg 4 . Willing able provide write informed consent inform requirement restriction study . Female subject childbearing potential must agree use highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sexual abstinence , vasectomise partner , non hormonal IUDs , double barrier method , instance , e.g . condom spermicide cream . 1 . History clinically relevant allergy know hypersensitivity Neramexane/ Memantine/Amantadine derivatives 2 . History clinically relevant allergy know hypersensitivity Clopidogrel 3 . Exposure another investigational agent within last two month Day 1 Period 1 4 . History clinically relevant allergy know hypersensitivity inactive ingredient use investigational product metabolic inhibitor 5 . Lactating pregnant female female plan become pregnant study conduct within 2 month end study 6 . Any contraindication indicate topically valid SPC Plavix® : severe hepatic impairment ; active pathological bleeding peptic ulcer intracranial hemorrhage Lack suitability trial : 7 . Any evidence significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal , endocrinological , metabolic disease screen 8 . History malignancy 9 . Any clinically relevant deviation clinical laboratory assessment 10 . ECG abnormalities clinical relevance , particular abnormal prolongation QT/QTcinterval ( i.e . QTc ≥ 450 m , PQ ≥ 220 m ) 11 . Systolic blood pressure &lt; 95 mmHg &gt; 150 mmHg diastolic blood pressure &lt; 50 mmHg &gt; 90 mmHg supine position 12 . Pulse rate &lt; 45 &gt; 100 beat per minute 13 . Chronic acute clinically relevant infection 14 . Acute chronic disease , especially psychiatric neurologic disorder 15 . History alcohol drug dependence 16 . Alcohol consumption average 40 g male 20 g female subject daily within last year 17 . Regular caffeine consumption average 1 L coffee and/or tea daily 1 L caffeinecontaining lemonade per day within last year 18 . Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence pharmacokinetics investigational medicinal product ( e.g . cholecystectomy , ulcus , etc . ) 19 . Anticipated donation spermatocytes oocyte medically assist reproduction technique [ ART ] within two month last dose present study 20 . Use prescribed medication four week prior first administration IMP . Regular use overthecounter drug 4 week prior first administration IMP Occasional use OTC drug ( except paracetamol , maximum 1 g/day ) within 2 week prior first administration IMP . Stable intake thyroid hormone substitution allow . 21 . Use food , food supplement medication know induce inhibit CYP3A4 cytochrome P450 enzymes within two week precede start study ( Day 1 ) , e.g . grapefruit , St. John 's wort 22 . Female subject employ form hormonal contraception within 2 month prior study Day 1 ( e.g . oral contraceptive , hormone release intrauterine contraceptive device [ IUDs ] , etc . ) 23 . Consumption xanthine derivates ( include caffeine ) within two day prior Day 1 24 . Smoker user snuff , nicotine replacement chew tobacco 25 . Previous enrolment clinical phase current study 26 . Positive result serology test 27 . Blood donation 450 mL within 60 day prior Day 1 28 . Positive pregnancy test , female 29 . Positive drug screen alcohol test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>